輝瑞向FDA提交數據 稱接種第三劑「復必泰」可恢復免疫有效率至95%
美國藥廠輝瑞(PFE.US)向美國食品及藥物管理局(FDA)提交數據,指出於以色列的實際情況顥示,接種第二劑「復必泰」新冠疫苗後半年接種第三劑,防禦新冠有效率可恢復至95%。輝瑞指,新冠疫苗有效性隨時間消退,但第三劑疫苗已顯示能產生與接種第二劑疫苗相若的免疫反應。有關數據於今年7月1日至8月30日期間收集。
《CNBC》報道,美國食品及藥物管理局官員拒絕就是否需要爲美國民衆接種第三劑疫苗表明立場,並指當局正檢視「復必泰」疫苗免疫效力減弱的潛在相關研究,不同研究亦發現不同結論,部分數據或相對更爲可靠。官員又指,以色列的數據爲觀察研究,嚴謹程度或與正式的臨牀測試不相同。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.